Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$5850.00
-130.00 (-2.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-15.3B · quality 33.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$82.1B
P/E
5.4x
↓EV/EBITDA
7.7x
↓ROE
10.9%
↑Gross Margin
45.6%
↓Debt/Equity
0.71
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.7%
FCF CAGR
—
FCF margin
-22.7%
FCF / Net income
-3.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $202.40B · net income $15.26B · FCF $-46.01B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $202.40B | $202.40B | $202.19B | $204.22B | $197.96B |
| Net Income | $15.26B | $15.26B | $15.47B | $12.54B | $24.32B |
| EBITDA | $20.96B | $20.96B | $24.23B | $25.93B | $39.00B |
| EPS | 1087.00 | 1087.00 | 1102.00 | 894.00 | 1733.00 |
| Gross Margin | 45.6% | 45.6% | 47.9% | 46.0% | 45.7% |
| Operating Margin | 5.8% | 5.8% | 9.2% | 9.2% | 18.4% |
| Net Margin | 7.5% | 7.5% | 7.7% | 6.1% | 12.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.71 | 0.71 | 0.47 | 0.33 | 0.36 |
| Current Ratio | 1.57 | 1.57 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-46.01B | $-46.01B | $-15.34B | $2.50B | $10.73B |
| Returns | |||||
| ROE | 10.9% | 10.9% | 12.3% | 11.5% | 23.6% |
| Valuation | |||||
| P/E | 5.38 | 5.38 | 6.39 | 10.11 | 5.03 |
| EV/EBITDA | 7.69 | 7.69 | 5.30 | 5.56 | 3.53 |
| P/B | 0.59 | 0.59 | 0.79 | 1.16 | 1.19 |
| Growth & Yield | |||||
| Revenue Growth | 0.1% | 0.1% | -1.0% | 3.2% | — |
| EPS Growth | -1.4% | -1.4% | 23.3% | -48.4% | — |
| Dividend Yield | 1.7% | 1.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-21.8%
EPS terminal req.
$519.09
Spread vs growth
20.5%
5Y implied EPS CAGR
-10.4%
EPS terminal req.
$628.10
Spread vs growth
9.0%
10Y implied EPS CAGR
-0.7%
EPS terminal req.
$1011.56
Spread vs growth
-0.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.8%
Start / end P/E
6.2x → 5.4x
EPS bridge
1102.00 → 1087.00
Residual
+0.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.